
The Veeva European Commercial & Medical Summit will begin tomorrow, seeing more than 800 industry leaders convene at the Marriot …

Bayer has been hit by the news that its latest effort in the pneumonia space failed at the Phase 3 …

It’s been a rocky year for AstraZeneca, it has scored some major successes yet its year has been marred by …

President Donald Trump’s budget proposes to cut funding to the National Institutes of Health by $7.2 billion or 21%. Researchers …

The UK government’s Autumn Budget struck a gloomy note for the economy, with figures pointing towards low productivity and the …

As Friday comes round again, this week saw some of the biggest news of the year: Amsterdam is the new …

Researchers, based in the US, have conducted a large-scale collection of publicly available data and found that significant differences can …

Caprice Bearden, a 63-year old ex-Director of Compliance for an Indiana-based Pharmakon, has been found guilty of introducing adulterated drugs …

A clinical trial is to be launched to test AstraZeneca’s experimental drug, AZD1775, for the treatment of head and neck …

Experts have developed a new form of therapy for patients living with schizophrenia, by allowing those individuals to speak to …

In good news for coffee drinkers, drinking three to four cups of coffee was found to lower the risk of …

Greg Alton, Executive Vice President of Corporate and Medical Affairs at Gilead, reveals how the rapid development and distribution of …

The European Commission has granted Tesaro’s Zejula (niraparib) marketing approval in Europe, it has emerged. Zejula is a poly (ADP-ribose) …

There is a general push in the UK to find new digital means of reducing the workload on doctors and …

Teva’s troubled year needs little detailing, those following the company have seen it lurch from one piece of bad news …